Evidence for Quantitative and Functional Immune Deviation in Pediatric Patients with Sickle Cell Disease  by Kean, L.S. et al.
Poster Session I S27524 months after transplantation and was lower during the first 120
days in the CD34 group than in the PBSC group (p\0.1, with p
\0.01 on day 40). This difference was more significant after exclud-
ing from the CD34 group patients who had received pre-emptive
DLI (p\0.05, with p\0.01 on days 40 and 60). T-cell repertoire di-
versity was similar in both groups on days 100 and 365 post-PBSCT
(with a median total number for the 24 BV families of 218 bands in
both groups on day 100 post-PBSCT and 223.5 and 236 bands for
the CD34 and PBSC groups respectively on day 365 (p 5 0.67)).
Conclusion: This study suggests that the T-cell depletion of the
graft induced a delayed immune reconstitution for naive CD4+ T
cells after allogeneic PBSCT with high dose conditioning.
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KINETICS OF IL-7 AND IL-15 LEVELS AFTER ALLOGENEIC PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION (ALLO-PBSCT) FOLLOWING
HIGH-DOSE OR NONMYELOABLATIVE CONDITIONING
De Bock, M., Fillet, M., Merville, M.-P., Gothot, A., Beguin, Y.,
Baron, F. University of Liege, Belgium
Background: Successful allo-PBSCT depends on the recovery of an
adequate immune system, allowing not only to prevent lethal infec-
tions but also to induce immune-mediated graft-versus-tumor ef-
fects. Previous studies have demonstrated that immune recovery
depends mainly on homeostatic peripheral expansion (HPE) of do-
nor T cells contained in the graft the first 3-6 mo. following allo-
PBSCT. IL-7 and IL-15 are the main driving forces of HPE, and
are secreted in response to lymphodepletion. While high-dose con-
ditioning regimens induce generally a profound lymphodepletion,
progressive replacement of host-derived by donor-derived T cells
is the rule after nonmyeloablative conditioning.
Patients and Methods: Data from 106 pts given allo-PBSCT after
high-dose (n 5 36) or low-dose TBI based nonmyeloablative (n 5
70) conditioning were analyzed. Among patients given high-dose
conditioning, 26 patients were given unmanipulated PBSC with
(n 5 24) or without (n 5 2) added ATG and 10 patients received
CD34-selected PBSC.No patient in the nonmyeloablative group re-
ceived ATG orCD-34 selected PBSC. IL-7 plasma and IL-15 serum
levels were measured with a commercial ELISA (R&D Systems,
Minneapolis, MN, USA). Lymphocyte subset counts were analyzed
by flow cytometry.
Results: CD4+ T cell and naive CD4+ T cell counts were lower
(P\0.001) on days 28, 40, 60, 80, 100 and 180 in pts given grafts after
high-dose than in those given nonmyeloablative conditioning. IL-7
levels were higher in pts given high-dose than in those given non-
myeloablative conditioning on days 7, 14, 28, 40, 60, 80 and 100 after
transplantation (p\0.01). Day 28 IL-7 levels were highly correlated
(r\-0.52, P\0.0001) with day 28 counts of T cells, CD4+ T cells,
CD8+ T cells, and naive CD4+ T cells but not with day 28 counts
of NK cells. IL-15 levels were higher in patients given high-dose
than in those given non-myeloablative conditioning on days 7
(p\0.01), 14 (p\0.01), and 28 (p 5 0.055) after transplantation.
There was a correlation between IL-15 levels and day 28 counts of
T cells (r 5 -0.30, P 5 0.002) and NK cells (r 5 -0.38, P 5 0.001).
Conclusions: Our data suggest that the physiology of immune re-
covery and particularly of HPE is significantly different in pts given
high-dose than in those given nonmyeloablative conditioning and
encourage further studies comparing immune recovery and immune
recovery mechanisms in pts given high-dose or nonmyeloablative
conditioning.194
EVIDENCE FOR QUANTITATIVE AND FUNCTIONAL IMMUNE DEVIATION
IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
Kean, L.S.1, Sen, S.1, Felder, M.A.1, Tangpricha, V.1, Adisa, O.1,
Herry, A.J.1, Buchanan, I.2, Ziegler, T.3, Alvarez, J.1, Beus, J.3,
Worthington-White, D.1, Robertson, J.3, George, J.4, Cetron, J.3,
Ofori-Acquah, S.F.1, Osunkwo, I.1 1Aflac Cancer Center and Blood
Disorders Service; 2Morehouse School of Medicine; 3Emory University;
4Sickle Cell Foundation of Georgia
While HSCT is a curative therapy for sickle cell disease (SCD),
SCD patients are at increased risk of graft rejection, especially afternon-myeloablative transplant. To determine whether immune
mechanisms might influence their increased risk of rejection, we
evaluated quantitative and functional immunologic differences be-
tween 23 pediatric SCD patients and 18 age- and ethnicity-matched
controls, using a prospective cross-sectional study design. All pa-
tients and controls were African American and were matched for
gender and age. All patients were at their clinical baseline during
evaluation: no patient was experiencing an acute complication of
SCD. Following informed consent, each subject underwent quanti-
tative flow cytometric immune analysis including enumeration of to-
tal WBC, ANC, ALC, total T cells, B cells and NK cells as well as
CD4+ and CD8+ naive and memory T cell subpopulations. Func-
tional immune assessment was also performed, using multiplexed
analysis of 25 serum cytokines.
Our results provide evidence for significant quantitative and func-
tional immune deviation in SCD patients compared to controls. In
addition to the well-documented increases in total WBC and ANC
(1.9-fold and 1.7-fold compared to controls, respectively, p\0.05),
SCD patients also demonstrated significantly higher total lympho-
cytes, monocytes and both cytotoxic and cytokine-secretingNK cells
(2.9, 2.4, and 2.2-fold compared to controls, p\0.01 for all). Circu-
lating B cells were significantly higher in SCD patients (3.3 fold, p5
0.0005). CirculatingT cells were also increased in SCDpatients, and
this effect was specific to CD4+ T cells (1.7-fold, p 5 0.002). There
was no difference in CD8+ T cells (p5 0.4). The increased CD4+ T
cell count predominantly involved memory CD4+ T subpopula-
tions, with both central and effector memory CD4+ T cells signifi-
cantly increased compared to controls (1.9-fold and 2.5-fold,
respectively, p\ 0.01). SCD patients also showed evidence of func-
tional immune activation at steady state; plasma cytokine analysis re-
vealed higher circulating CXCL10, CCL4 and IL-15 (2.4, 2.1, and
.10 fold compared to controls, p\0.05 for all).
Our results provide strong cellular and molecular evidence for
quantitative and functional immune deviation in SCD patients.
These observations suggest that strategies targeting NK cell, B
cell, and CD4T cell functionmay be required for successful engraft-
ment of SCD patients during non-myeloablative HSCT.
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SAFETY OF LIPOSOMAL CYTARABINE PROPHYLAXIS IN PEDIATRIC BONE
MARROWTRANSPLANT (BMT) RECIPIENTSWITH ACUTE LEUKEMIA (AL)
AND NON HODGKIN LYMPHOMA (NHL) AT HIGH RISK OF CNS RELAPSE
Hochberg, J., Duffy, D., Harrison, L., Morris, E., Cairo, M.S. New York
Medical College, Valhalla, NY
Liposomal Cytarabine (LC) is a derivative of cytarabine designed
for intrathecal treatment of leukemia/lymphomatous meningitis
(LLM). LC allows for sustained release with prolonged drug expo-
sure of 8 to 14 days in children and adults, respectively. Adult trials
have shown 50mg of LC to be both safe and effective in the treatment
of LLM (Glantz et al, JCO 1999). Bomgaars et al. investigated the
use of LC in children in a phase I dose escalation trial and demon-
strated the maximal tolerated dose to be 35mg and that it was safe,
well tolerated and effective (Bomgaars et al., JCO 2004). However,
there remains a paucity of data on the use of LC prophylaxis to pre-
vent LLM in pediatric allogeneic stem cell (AlloSCT) recipients.
Objective:We report on the safety and tolerability of liposomal cy-
tarabine prior to and following stem cell transplant in pediatric BMT
recipients with AL and NHL.
Methods:Pediatric stem cell recipients with a history of AL orNHL
and high risk of CNS disease received 35mg of LC (\21yr) or 50mg
(.21yr) via lumbar puncture or omaya reservoir pre conditioning
and every 3months for 1-2yrs post stem cell transplant. Patients re-
ceived dexamethasone (0.15mg/kg/dose BID) concomitantly x
5days. There were 8 matched unrelated donor transplants, 9
matched related donor transplants and 3 autologous transplants.
Twelve patients received a TBI (1200 cGy) containing conditioning
regimen. Seven patients received an additional CNS boost of up to
1200 cGy.
Results: To date there have been 21 patients: (12 ALL, 2 AML, 3
Burkitt, 3 DLBCL and 1 T-LL). At the time of transplant, 7 patients
were CR1/PR1, 10 patients CR2 and 4 patients CR3. Patients have
received a total of 46 doses (median 5 1, range 1-12). Median age:
12yr (range 6-22). Mean follow up: 517 days (median 5 294days).
Eight of 21 patients had a history of CNS AL/NHL involvement
